Crossmark

A prospective randomized-controlled non-blinded comparative study of the JAK inhibitor (baricitinib) with TNF-α inhibitors and conventional DMARDs in a sample of Egyptian rheumatoid arthritis patients

Crossref DOI link: https://doi.org/10.1007/s10067-024-07194-x

Published Online: 2024-10-31

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mahmoud, Esraa M.

Radwan, Abdullah

Elsayed, Sahar A. https://orcid.org/0000-0001-8755-1750
Funding

Funding for this research was provided by:

Sohag University
License Information

Text and Data Mining valid from 2024-10-31

Version of Record valid from 2024-10-31
More Information

Article History

Received: 23 July 2024

Revised: 11 October 2024

Accepted: 15 October 2024

First Online: 31 October 2024

Declarations

:

: This study was carried out in accordance with the ethical standards laid down in the Helsinki Declaration of 1975 and its later amendments in 2000, and approved by The Medical Research Ethics Committee, Faculty of Medicine—Sohag University under IRB registration number: Soh-Med-22–09-06. All patients included in this study gave written informed consent to participate in this research.

: The authors declare that they have no conflict of interest.

: It is a single-center, small sample-size study, limited by biological and targeted therapy costs.

Document is current

Any future updates will be listed below